Chemours Co is trading at $23.84 (up 6.8%), continuing a multi-session recovery as investors reconsider the sharp selloff that followed its Q1 2026 earnings report.
- The company beat EPS expectations in Q1 2026 while revenue met forecasts, yet shares initially plunged over 16% in premarket trading following the announcement.
- Today's upward momentum appears to be follow-through buying rather than a reaction to new company developments, as investors reassess what was previously viewed as an overreaction.